

Francesco Massari

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/706538/francesco-massari-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

384
papers

5,218
citations

38
h-index

54
g-index

461
ext. papers

6,816
ext. citations

5.1
avg. IF

5.93
L-index

#	Paper	IF	Citations
384	Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.. <i>Future Oncology</i> , 2022 ,	3.6	2
383	Acutely Symptomatic Hypoperfusion Through an Occluded Subclavian to Internal Carotid Artery Bypass Graft: Salvage Mechanical Thrombectomy and Graft Revascularization.. <i>Cureus</i> , 2022 , 14, e20881 ^{1.2}		
382	The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 170, 103596	7	0
381	The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: will immunotherapy solve the problem?. <i>Immunotherapy</i> , 2022 ,	3.8	1
380	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib.. <i>Therapeutic Advances in Medical Oncology</i> , 2022 , 14, 17588359221079580	5.4	0
379	Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.. <i>European Urology Focus</i> , 2022 ,	5.1	2
378	Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?. <i>Anticancer Research</i> , 2022 , 42, 1487-1493	2.3	0
377	CARE-compliant stereotactic radiotherapy of urothelial nodal metastases: A case report.. <i>Molecular and Clinical Oncology</i> , 2022 , 16, 85	1.6	
376	Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study.. <i>European Urology</i> , 2022 ,	10.2	0
375	Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.. <i>Current Oncology</i> , 2022 , 29, 1709-1722	2.8	1
374	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022 , 29, 3499-3518	3.5	0
373	Could double stain for p53/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?. <i>Pathology Research and Practice</i> , 2022 , 234, 153937	3.4	
372	Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis.. <i>Tumori</i> , 2022 , 3008916221090323	1.7	
371	The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy among Patients with Urothelial Carcinoma: A Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022 , 12, 842	3.6	0
370	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT.. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
369	First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.. <i>World Journal of Clinical Oncology</i> , 2021 , 12, 1037-1046	2.5	
368	GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak. <i>Therapeutic Advances in Urology</i> , 2021 , 13, 17562872211054302	3.2	1

367	Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis. <i>American Journal of Clinical Pathology</i> , 2021 ,	1.9	4
366	Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views. <i>Cancers</i> , 2021 , 13,	6.6	3
365	Ancient DNA SNP-panel data suggests stability in bluefin tuna genetic diversity despite centuries of fluctuating catches in the eastern Atlantic and Mediterranean. <i>Scientific Reports</i> , 2021 , 11, 20744	4.9	0
364	Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study. <i>Anti-Cancer Drugs</i> , 2021 , 32, 74-81	2.4	0
363	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. <i>European Urology Focus</i> , 2021 , 7, 955-963	5.1	3
362	Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1506-1520	2.3	7
361	Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. <i>European Urology Focus</i> , 2021 ,	5.1	17
360	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. <i>Translational Andrology and Urology</i> , 2021 , 10, 1562-1568	2.3	1
359	Narrative review: update on immunotherapy and pathological features in patients with bladder cancer. <i>Translational Andrology and Urology</i> , 2021 , 10, 1521-1529	2.3	5
358	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1530-1540	2.3	0
357	TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?-a narrative review. <i>Translational Andrology and Urology</i> , 2021 , 10, 1541-1552	2.3	2
356	Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience. <i>Pathology Research and Practice</i> , 2021 , 220, 153410	3.4	1
355	Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib. <i>BJU International</i> , 2021 , 128, 254-261	5.6	
354	Expected and non-expected immune-related adverse events detectable by CT. <i>European Journal of Radiology</i> , 2021 , 138, 109617	4.7	
353	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
352	Left Ventricular Noncompaction Cardiomyopathy as a Potential Cause of Bilateral Posterior Cerebral Artery Stroke - a Rare and Unique Clinical Occurrence. <i>American Journal of Case Reports</i> , 2021 , 22, e931103	1.3	0
351	Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 783-793	3.8	0
350	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021 , 26, 740-750	5.7	3

349	Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. <i>Immunotherapy</i> , 2021 , 13, 685-692	3.8	4
348	The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	5
347	Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy. <i>European Urology</i> , 2021 , 79, 887-889	10.2	1
346	Adjuvant immunotherapy in muscle-invasive urothelial carcinoma. <i>Lancet Oncology</i> , 2021 , 22, e237	21.7	1
345	Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials. <i>Pathology Research and Practice</i> , 2021 , 222, 153440	3.4	4
344	Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-7	2.2	4
343	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 1-8	5.9	24
342	Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review. <i>Future Oncology</i> , 2021 , 17, 2671-2681	3.6	2
341	Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 1225-1232	4.2	4
340	Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2021 , 7, 1068	13.4	
339	The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 35, 505-519	3.9	4
338	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 32-40	3.3	12
337	Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e84-e91	3.3	11
336	Re: Alfonso Gñez de Liañ Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. <i>Eur Urol</i> 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021 , 11, 721432	10.2	1
335	Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach. <i>European Journal of Cancer</i> , 2021 , 143, 75-77	7.5	2
334	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2021 , 13, 257-270	3.8	6
333	Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2021 ,	5.1	12
332	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. <i>Cancers</i> , 2021 , 13,	6.6	51

331	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. <i>Cancers</i> , 2021 , 13,	6.6	12
330	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	8
329	An update on investigational therapies that target STAT3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 245-251	5.9	3
328	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1581-1587	2.3	0
327	Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. <i>Pathology Research and Practice</i> , 2021 , 219, 153350	3.4	3
326	Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 1237-1243	5.5	1
325	Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity. <i>JAMA Oncology</i> , 2021 , 7, 1577	13.4	
324	A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. <i>Anti-Cancer Drugs</i> , 2021 ,	2.4	1
323	Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1876, 188547	11.2	4
322	Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study. <i>Targeted Oncology</i> , 2021 , 16, 625-632	5	2
321	Re: Thomas Powles, Jonathan E. Rosenberg, Guru P. Sonpavde, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>N Engl J Med</i> 2021;384:1125-35. <i>European Urology Oncology</i> , 2021 , 4, 670	6.7	2
320	An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 2323-2336	4	1
319	Re: Thomas Powles, Tibor Csizi, Mustafa Ugurlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. <i>Lancet Oncol</i> . In press. https://doi.org/10.1016/S1470-2045(21)00152-2 : The Conflict of Adding Immunotherapy to	6.7	
318	Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study <i>Urology (Meet-Uro)</i> 2021 , 99, 747-755	3.6	2
317	Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021 , 154, 120-127	7.5	22
316	A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34. <i>Pathology Research and Practice</i> , 2021 , 227, 153637	3.4	1
315	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	5
314	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. <i>Medicines (Basel, Switzerland)</i> , 2021 , 8,	4.1	1

313	Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?. <i>Diagnostics</i> , 2021 , 11,	3.8	5
312	Current androgen receptor antagonists under investigation for resistant prostate cancer.. <i>Expert Review of Anticancer Therapy</i> , 2021 , 1-12	3.5	1
311	Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2021 , 17, 61	5	5
310	Avelumab Maintenance for Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 2482	59.2	4
309	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. <i>Cells</i> , 2020 , 9,	7.9	26
308	Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers. <i>Diagnostics</i> , 2020 , 10,	3.8	0
307	Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
306	Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 491-501	3.5	6
305	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020 , 12,	6.6	38
304	Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.04.038 : Cytoreductive Nephrectomy: To Whom and When?. <i>European Urology Oncology</i> , 2020 , 3, 559-560	6.7	
303	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. <i>Immunotherapy</i> , 2020 , 12, 151-159	3.8	8
302	Cabazitaxel in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 1286	59.2	5
301	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
300	Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. <i>Eur Urol</i> . In press DOI: 10.1016/j.eururo.2020.04.065. <i>European Urology</i> , 2020 , 78, e205-e206	10.2	4
299	Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer. <i>Pathology Research and Practice</i> , 2020 , 216, 153012	3.4	3
298	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020 , 9,	7.9	2
297	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020 , 9,	7.9	4
296	Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncol</i> . In press. https://doi.org/10.1001/jamaoncol.2020.2218 : SAVOIR: From Own Goal to Winning Goal?. <i>European Urology Oncology</i> , 2020 , 3, 541-560	6.7	2

295	Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations. <i>European Urology</i> , 2020 , 78, 768-770	10.2	1
294	Epigenetic modulations and lineage plasticity in advanced prostate cancer. <i>Annals of Oncology</i> , 2020 , 31, 470-479	10.3	43
293	Similarities and Differences between Clear Cell Tubulo-Papillary and Conventional Clear Cell Renal Cell Carcinoma: A Comparative Phenotypical and Mutational Analysis. <i>Diagnostics</i> , 2020 , 10,	3.8	4
292	Renal Cell Carcinoma: genomic landscape and clinical implications. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020 , 5, 95-100	1.6	1
291	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , 2020 , 40, 211-226	3.2	7
290	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. <i>Cells</i> , 2020 , 9,	7.9	8
289	Distal radial access in the anatomical snuffbox for neurointerventions: a feasibility, safety, and proof-of-concept study. <i>Journal of NeuroInterventional Surgery</i> , 2020 , 12, 798-801	7.8	24
288	Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 751-751	2.2	3
287	Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS762-TPS762	2.2	
286	Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 754-754	2.2	
285	Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 701-701	2.2	
284	Trapped Embolic Protection Device: A Salvage Technique. <i>Cureus</i> , 2020 , 12, e9228	1.2	
283	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020 , 21, 1463-1475	3.5	4
282	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. <i>Current Drug Targets</i> , 2020 , 21, 1664-1671	3	3
281	PD-L1 Inhibitors for the Treatment of Prostate Cancer. <i>Current Drug Targets</i> , 2020 , 21, 1558-1565	3	1
280	Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 632-632	2.2	
279	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15080-e15080 ²	2.2	
278	Baseline and early change of neutrophil to lymphocyte ratio (bNLR and Δ NLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17081-e17081	2.2	

277	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1047-1059	5.4	3
276	Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 105-106	2.2	13
275	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 105-120	21.7	35
274	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 231-243	3.8	14
273	On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. <i>Annals of Oncology</i> , 2020 , 31, 1415-1416	10.3	21
272	Designing novel immunocombinations in metastatic renal cell carcinoma. <i>Immunotherapy</i> , 2020 , 12, 1257-1268	12.4	4
271	Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. <i>Cancer Genetics</i> , 2020 , 248-249, 57-62	2.3	4
270	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. <i>European Journal of Cancer</i> , 2020 , 138, 202-211	7.5	10
269	Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis. <i>Targeted Oncology</i> , 2020 , 15, 495-501	5	12
268	Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. <i>N Engl J Med</i> . In press. https://doi.org/10.1056/NEJMoa2022485 . <i>European Urology Oncology</i> , 2020 , 3, 806	6.7	1
267	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 755-763	3.5	7
266	Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clin Cancer Res</i> . In press. https://doi.org/10.1158/1078-0432.ccr-20-2063 . <i>European Urology Oncology</i> , 2020 , 3, 801-805	6.7	1
265	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020 , 9,	7.9	25
264	Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1329-1338	4.1	34
263	Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. <i>Lancet</i> 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease. <i>European Urology Oncology</i> , 2020 , 3, 390	6.7	1
262	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e83-e90	3.3	10
261	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020 , 87, 3-10	1.2	3
260	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 207-217	3.8	4

259	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 255-264	3.8	9
258	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 141-150	3.8	9
257	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019 , 11,	6.6	11
256	Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George Letter to the Editor re: Arnaud M Jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>Eur Urol</i> 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e339-e344	10.2	2
255	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019 , 11,	3.3	18
254	Comparison and optimization of genetic tools used for the identification of ancient fish remains recovered from archaeological excavations and museum collections in the Mediterranean region. <i>International Journal of Osteoarchaeology</i> , 2019 , 29, 365-376	6.6	21
253	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. <i>Frontiers in Oncology</i> , 2019 , 9, 228	1.1	2
252	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 631-643	5.3	14
251	Microbiome and Cancers, With Focus on Genitourinary Tumors. <i>Frontiers in Oncology</i> , 2019 , 9, 178	3.8	21
250	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019 , 39, 503-519	5.3	10
249	The effect of a treatment delay on outcome in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 529.e1-529.e7	3.2	23
248	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019 , 11,	2.8	4
247	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. <i>Cancers</i> , 2019 , 11,	6.6	20
246	Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1283-1289	6.6	15
245	BAP1 in solid tumors. <i>Future Oncology</i> , 2019 , 15, 2151-2162	3.8	12
244	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 141-152	3.6	17
243	Overview on Percutaneous Therapies of Disc Diseases. <i>Medicina (Lithuania)</i> , 2019 , 55,	7	11
242		3.1	3

241	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e871-e877	3.3	18
240	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , 2019 , 23, 569-577	4.5	6
239	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. <i>European Urology Oncology</i> , 2019 , 2, 603-604	6.7	1
238	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019 , 11, 1507-1521	3.8	15
237	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. <i>Current Drug Metabolism</i> , 2019 , 20, 305-312	3.5	7
236	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 572-572	2.2	
235	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. <i>Cancers</i> , 2019 , 12,	6.6	14
234	Re: Arnaud M Jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. <i>N Engl J Med</i> 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?. <i>European Urology</i>	6.7	3
233	New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?. <i>European Urology Oncology</i> , 2019 , 2, 471	6.7	2
232	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 917-927	2.5	2
231	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 42-45	2.7	12
230	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. <i>Journal of Clinical Pathology</i> , 2019 , 72, 135-139	3.9	17
229	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019 , 15, 563-565	3.6	1
228	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019 , 8,	7.9	20
227	CheckMate 214 patient-reported outcomes: listening to our patients. <i>Lancet Oncology, The</i> , 2019 , 20, 179-180	21.7	2
226	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018 , 10, 65-77	3.2	14
225	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018 , 64, 11-20	14.4	57
224	Atezolizumab for platinum-treated metastatic urothelial carcinoma. <i>Lancet, The</i> , 2018 , 391, 716-718	40	9

223	Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. <i>Lancet Oncol</i> 2018;19:405-15. <i>European Urology</i> , 2018, 74, e50	10.2	0
222	Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. <i>Cancer Treatment Reviews</i> , 2018, 67, 29-33	14.4	3
221	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 685-693	3.5	8
220	Pipeline Embolization Device for Pericallosal Artery Aneurysms: A Retrospective Single Center Safety and Efficacy Study. <i>Operative Neurosurgery</i> , 2018, 14, 351-358	1.6	10
219	The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. <i>Pathology and Oncology Research</i> , 2018, 24, 447-456	2.6	12
218	Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. <i>Eur Urol</i> 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: A Joint Study from the Metastasis 3 European Urology, 2018, 74, 118-119	10.2	2
217	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951	3.3	22
216	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 129, 124-132	7	11
215	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018, 14, 2559-2564	3.6	5
214	The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 705-709	2.4	1
213	Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018, 29, 710-715	2.4	5
212	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 80-85	14.4	18
211	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 645-655	3.8	13
210	Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 751-758	8.8	6
209	Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> 2018;73:62-8. <i>European Urology</i> , 2018, 73, e72	10.2	1
208	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38	9.8	206
207	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , 2018, 3, e000389	6	3
206	The Identification of Immunological Biomarkers in Kidney Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 456	5.3	32

205	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. <i>Frontiers in Oncology</i> , 2018 , 8, 653	5.3	39
204	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 397	5.3	15
203	Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 526.e13-526.e18	2.8	4
202	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2018 , 13, 705-714	5	24
201	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , 2018 , 29, 911-913	2.4	2
200	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018 , 10, 1229-1239	3.8	22
199	Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. <i>Future Oncology</i> , 2018 , 14, 2691-2699	3.6	2
198	Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?. <i>Lancet Oncology, The</i> , 2018 , 19, e437	21.7	
197	Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>Eur Urol</i> 2018;73:462-8. <i>European Urology</i> , 2018 , 74, e12-e13	10.2	
196	Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 355-359.e1	3.3	22
195	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1021-1025	10.25	13
194	Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience. <i>Tumori</i> , 2018 , 104, 128-136	1.7	11
193	Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017 , 25, 39-43	1.9	7
192	Tp53 and its potential therapeutic role as a target in bladder cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 401-414	6.4	24
191	The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. <i>Cancer Treatment Reviews</i> , 2017 , 55, 71-82	14.4	36
190	Use of self-expanding stents for better intracranial flow diverter wall apposition. <i>Interventional Neuroradiology</i> , 2017 , 23, 129-136	1.9	17
189	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. <i>Future Oncology</i> , 2017 , 13, 1105-1114	3.6	4
188	Use of the Pipeline embolization device for recurrent and residual cerebral aneurysms: a safety and efficacy analysis with short-term follow-up. <i>Journal of NeuroInterventional Surgery</i> , 2017 , 9, 1208-1213	7.8	23

187	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017 , 54, 68-73	14.4	52
186	Two-year single-center experience with the Baby TrevoPstent retriever for mechanical thrombectomy in acute ischemic stroke. <i>Journal of NeuroInterventional Surgery</i> , 2017 , 9, 541-546	7.8	21
185	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017 , 77, 1012-1019	4.2	4
184	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. <i>Eur Urol</i> 2017;71:790-807. <i>European Urology</i> , 2017 , 72, e139-e141	10.2	1
183	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 781-789	3.8	7
182	Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 541.e7-541.e13.8	13.8	9
181	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. <i>Immunotherapy</i> , 2017 , 9, 579-587	3.8	10
180	Re: Kenneth A. Iczkowski Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9. Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and	10.2	2
179	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 261-274	1.6	1
178	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017 , 60, 152-157	14.4	25
177	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017 , 16, 232-240	0.9	2
176	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. <i>European Urology Supplements</i> , 2017 , 16, 223-231	0.9	3
175	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. <i>Tumori</i> , 2017 , 103, 405-421	1.7	31
174	Wide spectrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach. <i>Oncotarget</i> , 2017 , 8, 7328-7335	3.3	16
173	Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutic target for patients at risk for bone metastases. <i>International Journal of Biological Markers</i> , 2017 , 32, e243-e247	2.8	7
172	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2266-2277	40	121
171	Immunotherapy in genitourinary cancers: where are we going?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 73-78	1.6	2
170	Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. <i>European Journal of Cancer</i> , 2017 , 83, 237-246	7.5	20

169	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. <i>Archives of Pathology and Laboratory Medicine</i> , 2017 , 141, 1460-1461	5	9
168	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 169-175	1.6	8
167	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. <i>Eur Urol</i> 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. <i>European Urology</i> , 2017 , 71, e73-e75	10.2	6
166	Epigenetic Modifications and Modulators in Prostate Cancer. <i>Critical Reviews in Oncogenesis</i> , 2017 , 22, 439-450	1.3	8
165	Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis. <i>Oncotarget</i> , 2017 , 8, 100708-100716	3.3	20
164	Urinary Biomarkers for Prostate Cancer. <i>Current Drug Metabolism</i> , 2017 , 18, 723-726	3.5	3
163	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. <i>Current Drug Metabolism</i> , 2017 , 18, 700-711	3.5	21
162	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. <i>Current Drug Metabolism</i> , 2017 , 18, 692-699	3.5	7
161	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. <i>Current Drug Metabolism</i> , 2017 , 18, 712-722	3.5	24
160	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. <i>Asian Journal of Andrology</i> , 2017 ,	2.8	1
159	Prostate cancer grading in 2016. <i>Minerva Urology and Nephrology</i> , 2017 , 69, 1-4	2.3	
158	Onyx embolization in distal dissecting posterior inferior cerebellar artery aneurysms. <i>Journal of NeuroInterventional Surgery</i> , 2016 , 8, 501-6	7.8	10
157	The role of precision medicine for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016 , 1, 369-377	1.6	2
156	Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2016 , 11, 569-577	5	12
155	E-091 Treatment of Aneurysms of the Pericallosal Artery with the Pipeline Embolization Device. <i>Journal of NeuroInterventional Surgery</i> , 2016 , 8, A90.1-A90	7.8	
154	E-040 Five-year Single Center Experience of Intracranial Aneurysm Treatment with the PED in Patients of different Age Groups. <i>Journal of NeuroInterventional Surgery</i> , 2016 , 8, A65.1-A65	7.8	
153	E-070 Endovascular Techniques for Achievement of Better Flow Diverter Wall Apposition. <i>Journal of NeuroInterventional Surgery</i> , 2016 , 8, A79.1-A79	7.8	
152	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: Game Over?. <i>Targeted Oncology</i> , 2016 , 11, 431-46	5	5

151	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
150	Chemohormonal Therapy in Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 287	59.2	2
149	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 57-75	5.5	39
148	Monotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection. <i>Journal of NeuroInterventional Surgery</i> , 2016 , 8, e13	7.8	6
147	Endovascular reconstruction of unruptured intradural vertebral artery dissecting aneurysms with the Pipeline embolization device. <i>Journal of NeuroInterventional Surgery</i> , 2016 , 8, 1048-51	7.8	30
146	ARTS (Aspiration-Retriever Technique for Stroke): Initial clinical experience. <i>Interventional Neuroradiology</i> , 2016 , 22, 325-32	1.9	104
145	2015 and human cancer: back to overall survival. <i>Future Oncology</i> , 2016 , 12, 1751-4	3.6	
144	Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?. <i>European Urology</i> , 2016 , 69, 969-70	10.2	3
143	Adjuvant Carboplatin Treatment in 115 Patients With Stage I Seminoma: Retrospective Multicenter Survey. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e161-9	3.3	9
142	Endovascular Treatment of Cerebral Aneurysms 2016 , 1071-1088.e6		1
141	Metabolic phenotype of bladder cancer. <i>Cancer Treatment Reviews</i> , 2016 , 45, 46-57	14.4	117
140	Safety, efficacy, and short-term follow-up of the use of Pipeline Embolization Device in small (. <i>Neuroradiology</i> , 2016 , 58, 267-75	3.2	51
139	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 254-63	7	1
138	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016 , 43, 27-35	14.4	41
137	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016 , 11, 345-51	5	48
136	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 48-55	3.3	14
135	Morphology and Species Composition of Southern Adriatic Sea Leptocephali Evaluated Using DNA Barcoding. <i>PLoS ONE</i> , 2016 , 11, e0166137	3.7	4
134	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 33381-90	3.3	10

133	Metabolic Alterations in Renal and Prostate Cancer. <i>Current Drug Metabolism</i> , 2016 , 17, 150-5	3.5	13
132	An Overview of Emerging Immunotargets of Genitourinary Tumors. <i>Current Drug Targets</i> , 2016 , 17, 750-6		8
131	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016 , 17, 757-70	3	6
130	Emerging Immunotargets and Immunotherapies in Prostate Cancer. <i>Current Drug Targets</i> , 2016 , 17, 777-82		7
129	Utilization of a New Intracranial Support Catheter as an Intermediate Aspiration Catheter in the Treatment of Acute Ischemic Stroke: Technical Report on Initial Experience. <i>Cureus</i> , 2016 , 8, e617	1.2	7
128	Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 553-553	2.2	
127	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 547-547	2.2	1
126	Do pathological parameters of primary tumor correlate with overall survival (OS) of metastatic clear-cell renal cell carcinoma (ccRCC)?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 549-549	2.2	
125	Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 231-231	2.2	
124	mTOR Pathway in Renal Cell Carcinoma 2016 , 417-428		
123	Prognostic role of body mass index (BMI) in patients with metastatic castration resistant prostate cancer (mCRPC) receiving chemotherapy: Preliminary results from a retrospective Italian multicenter study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 342-342	2.2	
122	PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16543 ² -e16543 ²		
121	Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?. <i>Oncology Reviews</i> , 2016 , 10, 293	4.3	38
120	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016 , 17, 771-6	3	12
119	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016 , 7, 54564-54571	3.3	89
118	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016 , 11, e0158952	3.7	39
117	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016 , 7, 376	5.6	93
116	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <i>BioDrugs</i> , 2016 , 30, 263-73	7.9	19

115	The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 681-96	3.5	6
114	Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 255-63	4.5	9
113	The prospect of precision therapy for renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2016 , 49, 37-44	14.4	42
112	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 10	12.8	50
111	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
110	Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. <i>Annals of Oncology</i> , 2015 , 26, 2107-13	10.3	66
109	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21	2.8	6
108	Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. <i>Future Oncology</i> , 2015 , 11, 1809-28	3.6	16
107	BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1201-10	3.8	63
106	Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1037-48	3.5	4
105	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015 , 41, 767-76	14.4	55
104	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
103	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 809-24	5.9	34
102	Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy. <i>Anti-Cancer Drugs</i> , 2015 , 26, 469-73	2.4	0
101	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <i>Future Oncology</i> , 2015 , 11, 107-19	3.6	11
100	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015 , 11, 2881-91	3.6	10
99	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. <i>Cellular and Molecular Immunology</i> , 2015 , 12, 122-4	15.4	2
98	The origin of prostate metastases: emerging insights. <i>Cancer and Metastasis Reviews</i> , 2015 , 34, 765-73	9.6	28

97	Kidney cancer and 2014: is innovation really over?. <i>Future Oncology</i> , 2015 , 11, 1437-49	3.6	1
96	Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2015 , 68, 154-60	10.2	37
95	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 50-9	7	11
94	Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 41-7	2.5	43
93	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015 , 136, 1-10	7.5	41
92	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. <i>Future Science OA</i> , 2015 , 1, FSO29	2.7	2
91	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015 , 115, 764-71	5.6	16
90	E-131 endovascular reconstruction of intradural vertebral artery fusiform dissecting aneurysms with the pipeline embolization device. <i>Journal of NeuroInterventional Surgery</i> , 2015 , 7, A101.2-A101	7.8	
89	P-014 arts (ace-retriever technique for stroke): initial clinical experience. <i>Journal of NeuroInterventional Surgery</i> , 2015 , 7, A29.1-A29	7.8	
88	Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2015 , 9, 263-7	1.2	6
87	Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder. <i>PLoS ONE</i> , 2015 , 10, e0127908	3.7	18
86	Monotherapy with stenting in subarachnoid hemorrhage (SAH) after middle cerebral artery dissection. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	
85	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015 , 41, 614-22	14.4	18
84	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 81-90	7	45
83	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015 , 11, 1381-8	3.6	5
82	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1367-9	3.5	16
81	Role of STAT3 pathway in genitourinary tumors. <i>Future Science OA</i> , 2015 , 1, FSO15	2.7	39
80	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 206-19	7	20

79	Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II- α amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel. <i>Clinical Breast Cancer</i> , 2015 , 15, 16-23	3	5
78	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
77	Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. <i>Journal of Urology</i> , 2015 , 193, 1905-10	2.5	9
76	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015 , 10, 325-36	5	13
75	PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. <i>Cancer Treatment Reviews</i> , 2015 , 41, 114-21	14.4	126
74	Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15594-e15594	2.2	1
73	High neutrophil to lymphocyte ratio (NLR) persistence during enzalutamide to predict poor clinical outcome in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16059-e16059	2.2	2
72	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015 , 6, 32161-8	3.3	24
71	Bladder cancer: molecular determinants of personalized therapy. <i>Current Drug Targets</i> , 2015 , 16, 115-24	3	14
70	Primary resistance to abiraterone acetate (AA) after docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC): A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 206-206	2.2	
69	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15595-e15595	2.2	1
68	Three-year results of repaired Barlow mitral valves via right minithoracotomy versus median sternotomy in a randomized trial. <i>Cardiology</i> , 2014 , 128, 97-105	1.6	14
67	P-007 Incidence and Management of Intimal Hyperplasia at 6 months after Flow Diversion for Intracranial Aneurysms. <i>Journal of NeuroInterventional Surgery</i> , 2014 , 6, A24.1-A24	7.8	1
66	Percutaneous ethanol embolization and cement augmentation of aggressive vertebral hemangiomas at two adjacent vertebral levels. <i>Journal of Neuroradiology</i> , 2014 , 41, 269-74	3.1	10
65	Combining percutaneous pedicular and extrapedicular access for tumor ablation in a thoracic vertebral body. <i>Interventional Neuroradiology</i> , 2014 , 20, 603-8	1.9	5
64	CXC and CC chemokines as angiogenic modulators in nonhaematological tumors. <i>BioMed Research International</i> , 2014 , 2014, 768758	3	43
63	E-041 Use of Flow Diverters in the Endovascular Reconstruction of Fusiform Dissecting Vertebral Artery Aneurysms. <i>Journal of NeuroInterventional Surgery</i> , 2014 , 6, A56.2-A57	7.8	1
62	Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. <i>Pathology</i> , 2014 , 46, 523-6	1.6	2

61	E-042 Use of Flow Diverters in Vessels less than 2.5 mm during Intracranial Aneurysm Treatment. <i>Journal of NeuroInterventional Surgery</i> , 2014 , 6, A57.1-A57	7.8	
60	Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 135-45	7	11
59	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 321-31	9.6	21
58	Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5089-5089	2.2	3
57	Enzalutamide activity in patients with metastatic castration resistant prostate cancer (mCRPC) previously responding to antiandrogen withdrawal syndrome (AWS): A preliminary report.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16058-e16058	2.2	1
56	Safety and clinical outcome of a cohort of patients (pts) with castration resistant prostate cancer (CRPC) treated with abiraterone acetate (AA) in a named patient program (NPP): Updated results of a retrospective study from an Italian cooperative group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 253-253	2.2	1
55	Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. <i>American Journal of Cancer Research</i> , 2014 , 4, 907-15	4.4	3
54	Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a Hard days night? <i>Current Pharmaceutical Design</i> , 2014 , 20, 3958-72	3.3	10
53	Treatment and outcome(s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15568-e15568	2.2	
52	A proposed new model for prognostic stratification of poor-risk patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15588-e15588 ^{2.2}	2.2	
51	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 214-214	2.2	
50	Prognostic value of flare-up phenomenon after discontinuation of sunitinib (SU) or pazopanib (PA) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 448-448	2.2	
49	Suitability of clear cell renal cell carcinoma to heat shock proteins-inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 480-480	2.2	
48	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 421-421	2.2	
47	Dose calculation and tolerability of adjuvant AUC 7 carboplatin in 100 patients with stage I seminoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 374-374	2.2	
46	Adenocarcinoma of the paraurethral glands: a case report. <i>Histology and Histopathology</i> , 2014 , 29, 1295-303	3.3	4
45	Clinical meta-analyses of targeted therapies in adenocarcinoma. <i>Targeted Oncology</i> , 2013 , 8, 35-45	5	3
44	Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 471-6	3.3	19

43	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1757-68	7.4	92
42	Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort. <i>European Journal of Cancer</i> , 2013 , 49, 2134-42	7.5	55
41	Intracranial atheromatous disease treatment with the Wingspan stent system: evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115, 741-7	2	9
40	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. <i>Tumori</i> , 2013 , 99, 637-649	1.7	18
39	PROFILING non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 597-608	4	6
38	Chemotherapy in metastatic renal cell carcinoma today? A systematic review. <i>Anti-Cancer Drugs</i> , 2013 , 24, 535-54	2.4	58
37	Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. <i>British Journal of Cancer</i> , 2013 , 109, 686-93	8.7	20
36	Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e105-6	8.9	13
35	Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013 , 13, 872-86	2.2	5
34	Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMA approval.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e17555-e17555	2.2	0
33	How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16053-e16053	2.2	0
32	HER2/neu gene determination in women screened for breast carcinoma: how screening programs reduce the skyrocketing cost of targeted therapy. <i>Anticancer Research</i> , 2013 , 33, 3705-10	2.3	2
31	Acute stroke treatment using the Penumbra endovascular mechanical thrombolysis device: a single-centre experience. <i>Radiologia Medica</i> , 2012 , 117, 1199-214	6.5	3
30	FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 103	12.8	31
29	True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugs. <i>PLoS ONE</i> , 2012 , 7, e49689	3.7	10
28	E-043 Image guided sympathetic blocks. <i>Journal of NeuroInterventional Surgery</i> , 2012 , 4, A64.2-A64	7.8	
27	E-044 Percutaneous image guided c-spine procedures. <i>Journal of NeuroInterventional Surgery</i> , 2012 , 4, A65.1-A65	7.8	
26	Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14661-e14661	2.2	1

25	PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4541-4541	2.2	23
24	Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 630-630	2.2	
23	Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA). <i>Lung Cancer</i> , 2011 , 73, 78-88	5.9	4
22	Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 115	12.8	23
21	Diagnostic and therapeutic joint injections. <i>Seminars in Interventional Radiology</i> , 2010 , 27, 160-71	1.6	36
20	Is 3T-MR spectroscopy a predictable selection tool in prophylactic vertebroplasty?. <i>CardioVascular and Interventional Radiology</i> , 2010 , 33, 1243-52	2.7	3
19	Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies. <i>Endocrine-Related Cancer</i> , 2009 , 16, 1241-9	5.7	13
18	Continuous i.v. infusion of remifentanyl and intraosseous lidocaine provide better analgesia than intraosseous lidocaine alone in percutaneous vertebroplasty of osteoporotic fractures. <i>British Journal of Anaesthesia</i> , 2009 , 103, 901-2	5.4	4
17	Future directions in percutaneous vertebroplasty. <i>Radiologia Medica</i> , 2009 , 114, 976-83	6.5	10
16	Percutaneous vertebroplasty in the management of vertebral osteoporotic fractures. Short-term, mid-term and long-term follow-up of 285 patients. <i>Skeletal Radiology</i> , 2009 , 38, 863-9	2.7	16
15	Percutaneous vertebroplasty in 1,253 levels: results and long-term effectiveness in a single centre. <i>European Radiology</i> , 2009 , 19, 165-71	8	39
14	Percutaneous vertebroplasty in multiple myeloma vertebral involvement. <i>Journal of Spinal Disorders and Techniques</i> , 2008 , 21, 344-8		39
13	Nucleoplasty in the treatment of lumbar diskogenic back pain: one year follow-up. <i>CardioVascular and Interventional Radiology</i> , 2007 , 30, 426-32	2.7	30
12	Percutaneous vertebroplasty in painful schmorl nodes. <i>CardioVascular and Interventional Radiology</i> , 2006 , 29, 97-101	2.7	26
11	Sacroplasty and iliac osteoplasty under combined CT and fluoroscopic guidance. <i>Spine</i> , 2006 , 31, E667-9	3.3	25
10	MRI and bone scan imaging in the preoperative evaluation of painful vertebral fractures treated with vertebroplasty and kyphoplasty. <i>In Vivo</i> , 2005 , 19, 1055-60	2.3	23
9	Kyphoplasty: a new opportunity for rehabilitation of neurologic disabilities. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2004 , 83, 810-2	2.6	4
8	Vertebroplasty and kyphoplasty in the treatment of malignant vertebral fractures. <i>Journal of Chemotherapy</i> , 2004 , 16 Suppl 5, 30-3	2.3	35

7	Percutaneous kyphoplasty: new treatment for painful vertebral body fractures. <i>In Vivo</i> , 2004 , 18, 149-53	2.3	11
6	Percutaneous kyphoplasty: indications and technique in the treatment of vertebral fractures from myeloma. <i>Tumori</i> , 2004 , 90, 22-6	1.7	5
5	Radiofrequency Heat Ablation and Vertebroplasty in the treatment of neoplastic vertebral body fractures. <i>Anticancer Research</i> , 2004 , 24, 3129-33	2.3	31
4	Could migraine be a "protective factor" against tumors?. <i>International Journal of Neuroscience</i> , 1994 , 75, 139-43	2	2
3	On the physiological significance of tumor necrosis factor-alpha in the human amniotic fluid. <i>Immunopharmacology and Immunotoxicology</i> , 1992 , 14, 749-56	3.2	2
2	Interleukin-1 beta and beta-endorphin circadian rhythms are inversely related in normal and stress-altered sleep. <i>International Journal of Neuroscience</i> , 1992 , 63, 299-305	2	34
1	Increased spontaneous release of tumor necrosis factor-alpha/cachectin in headache patients. A possible correlation with plasma endotoxin and hypothalamic-pituitary-adrenal axis. <i>International Journal of Neuroscience</i> , 1991 , 61, 53-60	2	19